Phaseline

Companies › VM Oncology

VM Oncology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VMD-928
TrkA inhibitor
NTRK1Phase 1Head and Neck CarcinomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03556228VMD-928Phase 1Head and Neck CarcinomaOncologyDec 2027

Targets

NTRK1 (1)

Companies with the same targets

Xuanzhu Biopharmaceutical Dompé Farmaceutici Nuvation Bio Roche Turning Point Therapeutics Bristol-Myers Squibb Teligene US Bayer

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.